Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19

Richard M. Burwick[1], Sigal Yawetz[2,3], Kathryn E. Stephenson[3,4], Ai-Ris Y. Collier[3,4], Pritha Sen[3,5], Brian G. Blackburn[6], E. Milunka Kojic[7], Adi Hirshberg[8], Jose F Suarez[6], Magdalena E. Sobieszczyk[9], Kristen M. Marks[10], Shawn Mazur[11], Cecilia Big[12], Oriol Manuel[13], Gregory Morlin[14], Suzanne J. Rose[15], Mariam Naqvi[1], Ilona T. Goldfarb[3,5], Adam DeZure[16], Laura Telep[16], Susanna K. Tan[16], Yang Zhao[16], Tom Hahambis[16], Jason Hindman[16], Anand P. Chokkalingam[16], Christoph Carter[16], Moupali Das[16], Anu O. Osinusi[16], Diana M. Brainard[16], Tilly A. Varughese[17], Olga Kovalenko[17], Matthew D. Sims[19], Samit Desai[19], Geeta Swamy[20], Jeanne S. Sheffield[21], Rebecca Zash[3,4], William R. Short[8]

[1]Cedars Sinai Medical Center, Obstetrics and Gynecology, Los Angeles, CA, United States;

[2]Brigham and Women's Hospital, Department of Medicine, Boston, MA, United States;

[3]Harvard Medical School, Boston, MA, United States;

[4]Beth Israel Deaconess Medical Center, Boston, MA, United States;

[5]Massachusetts General Hospital, Boston, MA, United States;

[6]Stanford University, Stanford, CA, United States;

[7]Mount Sinai Morningside and West, New York, New York, United States;

[8]Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, United States;

[9]Columbia University, New York, NY, United States;

[10]Weill Cornell Medicine, New York, NY, United States;

[11]NewYork Presbyterian/Weill Cornell Medical Center, New York, NY, United States;

[12]Beaumont Hospital, Dearborn, MI, United States;

[13]Lausanne University Hospital, Lausanne, Switzerland;

[14]Valley Medical Center, Renton, WA, United States;

[15]Stamford Health, Stamford, CT, United States;

[16]Gilead Sciences Inc., Foster City, CA, United States;

[17]Rutgers New Jersey Medical School, Newark, NJ, United States;

[18]Beaumont Hospital, Royal Oak, MI, United States;

[19]Hackensack Meridian, Hackensack University Medical Center, Hackensack, NJ, United States;

[20]Duke University School of Medicine, Durham, NC, United States;

[21]Johns Hopkins Medicine, Baltimore, MD, United States

Corresponding author:

Moupali Das, MD, MPH

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, CA 94404

Telephone: 650- 522-4511

Summary: Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate use remdesivir, recovery rates from serious infection were high with a low rate of serious adverse events.

ABSTRACT

BACKGROUND

Remdesivir is efficacious for severe COVID-19 in adults, but data in pregnant women are limited. We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated with remdesivir.

METHODS

Reported data span March 21 to June 16, 2020 for hospitalized pregnant women with PCR-confirmed SARS-CoV-2 infection and room air oxygen saturation ≤94% whose clinicians requested remdesivir through the compassionate use program. The intended remdesivir treatment course was 10 days (200mg on Day 1, followed by 100mg for Days 2-10, given intravenously).

RESULTS

Nineteen of 86 women delivered before their first dose and were reclassified as immediate "postpartum" (median postpartum day=1; range 0-3). At baseline, 40% of pregnant women (median gestational age 28 weeks) required invasive ventilation, in contrast to 95% of postpartum women (median gestational age at delivery 30 weeks). By Day 28 of follow-up, the level of oxygen requirement decreased in 96% and 89% of pregnant and postpartum women, respectively. Among pregnant women, 93% of those on mechanical ventilation were extubated, 93% recovered, and 90% were discharged. Among postpartum women, 89% were extubated, 89% recovered, and 84% were discharged. Remdesivir was well tolerated, with a low incidence of serious adverse events (16%). Most adverse events were related to pregnancy and underlying disease; most laboratory abnormalities were Grades 1 or 2. There was one maternal death attributed to underlying disease and no neonatal deaths.

CONCLUSIONS

Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate use remdesivir, recovery rates were high, with a low rate of serious adverse events.

Keywords: remdesivir, pregnant, COVID-19, ventilation, recovery

MAIN TEXT

INTRODUCTION

COVID-19, caused by SARS-CoV-2 infection, presents from asymptomatic disease to hypoxemic respiratory failure and death. Over 16.8 million confirmed cases and over 662,095 deaths have been reported to the World Health Organization as of July 30, 2020. [1] Remdesivir (GS-5734) is a nucleotide analogue that reduces SARS-CoV-2 replication in vitro through selective inhibition of viral RNA-dependent, RNA polymerase, which SARS-CoV-2 utilizes for replication within host cells.[2,3] In rhesus macaques infected with SARS-CoV-2, therapeutic remdesivir reduces clinical disease and lung damage.[4] In the Adaptive COVID-19 Treatment Trial (ACTT-1) study in nonpregnant hospitalized adults with severe COVID-19, remdesivir for 10 days was superior to placebo in reducing time to recovery, and the SIMPLE trial showed that 5 days of remdesivir resulted in similar outcomes when compared to 10 days.[5,6] Based on these data, emergency-use authorization (EUA) was granted by the United States (U. S.) Food and Drug Administration (FDA) for treatment of adults and children with severe COVID-19 disease.[7]

Women of reproductive age have comprised 21% of all SARS-CoV-2 cases reported to the U.S. Centers for Disease Control and Prevention (CDC) from January 22 – June 7, 2020, 9% of whom were pregnant.[8] Like nonpregnant adults, pregnant women with confirmed SARS-CoV-2 infection develop severe or critical illness in 9-14% of cases.[9,10] However, compared to age-matched nonpregnant women with COVID-19, pregnant women are more likely to be hospitalized, admitted to the intensive care unit (ICU), and require invasive mechanical ventilation.[8] In a cohort of 64 pregnant women hospitalized with severe or critical COVID-19 at 12 U.S. institutions, adverse pregnancy outcomes were also common, with high rates of preterm birth and cesarean delivery, and most deliveries necessitated due to maternal disease status.[11]

There are limited data regarding treatment of COVID-19 in pregnant women, and most come from small case series and case reports.[12-14] Pregnant women have been excluded from clinical trials evaluating remdesivir for COVID-19. However, since March 21, 2020, clinicians were able to request remdesivir for use in pregnant women with severe COVID-19, through a compassionate use program. Remdesivir is now available for pregnant women with severe COVID-19 through the EUA as of May 1, 2020. In this report, we describe outcomes in the first 86 pregnant women hospitalized for severe COVID-19 who were treated with compassionate use remdesivir.

METHODS

Compassionate use program description and population

Gilead Sciences began accepting requests from clinicians for compassionate use of remdesivir in pregnant women with COVID-19 on March 21, 2020 via a single patient protocol (available at https://academic.oup.com/cid). Access through compassionate use was limited to hospitalized patients with severe COVID-19, defined as presence of SARS-CoV-2 infection, confirmed by reverse transcriptase-polymerase chain reaction assay, and either oxygen saturation of 94% or less while breathing ambient air or need for oxygen support.[15-17] Exclusion criteria included creatinine clearance (by Cockcroft-Gault) of <30 ml per minute, serum levels of alanine aminotransferase (ALT) >5 times the upper limit of normal, or evidence of multi-organ failure. Remdesivir is not administered in persons with severe renal impairment due to concern of clearance of cyclodextrin in the intravenous formulation; remdesivir is not associated with renal toxicity. Clinicians were asked not to administer other investigational agents concurrently with remdesivir. The intended remdesivir treatment course was 10 days and comprised a loading dose of 200 mg intravenously (Day 1), plus 100 mg intravenously (Days 2-10). Supportive therapy and study drug discontinuation were at clinicians' discretion. There was no predetermined number of patients or sites or duration for the program. We report the first 86 women who were pregnant at the time of approval of remdesivir through compassionate use on or before April 22, 2020; they were followed through discharge or death or through 28 days post initiation. Of these 86 women, 19 women had already delivered by the time they received remdesivir and are referred to herein as the immediate "postpartum" group (median postpartum day=1; range 0-3). Data for some patients included in this analysis have been reported previously in case reports.[12-14]

Procedures

This program had no prespecified endpoints. An electronic case report form was used by clinicians to report clinical status, remdesivir administration, adverse events, selected laboratory results, and pregnancy outcomes, when applicable. No further follow-up under the protocol was required after hospital discharge.

Outcomes

The main clinical outcome was recovery; (1) for women on room air at baseline (ie, entry into the compassionate use program), recovery was defined as discharge; or (2) for women who were hypoxic and on oxygen support of any kind at baseline, recovery was defined as improving to room air or discharge. For patients on invasive mechanical ventilation at baseline, we report extubation and time to extubation. Changes in oxygen status are reported using the modified ordinal scale (Appendix Figure 1).[9,17,18] which includes the following categories: (6) death, (5) hospitalized, requiring invasive mechanical ventilation and/or ECMO, (4) hospitalized, requiring high-flow oxygen therapy and/or non-invasive positive pressure ventilation (NIPPV), (3) hospitalized, requiring supplemental low-flow oxygen therapy, (2) hospitalized on room-air, (1) not hospitalized (discharge).

We report 2-point improvement or any (1-point) improvement in the ordinal scale. Pregnancy outcomes (reported by treating clinicians), included gestational age at delivery, cesarean delivery, and emergent cesarean delivery. Safety was assessed by adverse events and treatment-emergent laboratory abnormalities.

Statistical Methods

Our population included all women who were pregnant at the time of approval for compassionate use of remdesivir on or before April 22, 2020, who had known delivery status on Day 1 of dosing, and for whom clinical data for baseline and at least one subsequent day were available. Baseline demographic, clinical and pregnancy characteristics were obtained and stratified by whether participants were pregnant or postpartum prior to remdesivir initiation. No sample size calculation was performed.

We report proportions of patients achieving key clinical outcomes by Day 28 and used a competing risk analysis approach, with death as the competing risk, to evaluate time to clinical recovery and time to extubation. Cox proportional hazards regression was used to assess associations between pretreatment characteristics and reported outcomes. We examined associations of the following demographic and clinical characteristics with risk of recovery: 1) baseline invasive ventilation, 2) age (< vs ≥35 years), 3) duration of symptoms (< vs ≥9 days), and 4) gestational age (<24, 24-32, >32 weeks). Results are reported as hazard ratio (HR) point estimates and 95% confidence intervals (CIs). The same approach was used for risk of extubation among patients with baseline invasive ventilation.

Pregnancy outcomes were stratified by presence of at least one risk factor for high-risk pregnancy. Those included: (a) preeclampsia, chronic hypertension, diabetes (gestational or pre-gestational), chronic kidney disease, systemic lupus erythematosus and or obesity; b) multi-fetal gestation; or c) age ≥35 years.

Adverse events and treatment-emergent laboratory abnormalities are summarized. The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Event, Version 2.1 (July 2017) was used for assigning toxicity grades (0 to 4) to laboratory results.[19] All analyses were conducted using SAS software, version 9.4 (SAS Institute).

RESULTS

Baseline Demographics and Clinical Characteristics

From Mar 21, 2020, 86 pregnant women were approved for participation in the remdesivir compassionate use program. Sixty-seven initiated remdesivir while pregnant and 19 initiated it immediately postpartum (median postpartum day=1; range 0-3). The median maternal age was 33 years (range 20-43), and 41% were 35 years or older; there was no difference in median age in pregnant compared with postpartum women (Table 1). Ninety-one percent of women were treated in the U.S. (Appendix Table 2). At remdesivir initiation, all women in the postpartum group were in the ICU compared to 67% of pregnant women; all but one of the postpartum women required mechanical invasive ventilation, compared with 40% of pregnant women. One postpartum woman required veno-venous extracorporeal membrane oxygenation (v-v ECMO). Median duration of symptoms prior to hospitalization was nine days, and median duration of hospitalization prior to initiation of remdesivir was three days, in both groups. In pregnant women, the most common comorbid medical conditions were: obesity (16%), asthma (13%), gestational diabetes (10%), and chronic hypertension (9%); among postpartum women: obesity (21%), gestational diabetes (11%), and chronic hypertension (5%). The median (IQR) number of remdesivir doses was 8 (5-10) for pregnant women, and 10 (9-10) for postpartum women. Although clinicians were asked not to administer other investigational agents concurrently with remdesivir, 37% of pregnant women also received hydroxychloroquine and 34% received azithromycin; 37% of postpartum women received hydroxychloroquine and 11% received azithromycin. One person in each group received tocilizumab and one pregnant woman received lopinavir/ritonavir.

Clinical Outcomes

The proportion of patients who experienced recovery within 28 days was high among both pregnant and postpartum women. Ninety-three percent of pregnant women and 89% of postpartum women have recovered (Appendix Figure 1). The highest rates of clinical improvement were among pregnant women not requiring invasive ventilation, of whom 98% recovered, 95% were discharged, 98% had any clinical improvement, and 95% had a 2-point improvement. Of women requiring invasive mechanical ventilation at baseline, rates of clinical improvement within 28 days were similar in pregnant and postpartum women: survival to discharge, 82% and 83%; any improvement, 93% and 89%; and ≥2-point improvement, 89% and 89%, respectively.

Among pregnant women, 93% recovered and 90% were discharged, with 96% exhibiting any clinical improvement (1 point on ordinal scale, Figure 1a, blue shading), and 93% experiencing a 2-point improvement on the ordinal scale. Among postpartum women, 90% recovered and 84% were discharged, with 89% exhibiting any clinical improvement (Figure 1b, blue shading) and 90% exhibiting a 2-point improvement. Among pregnant women, median time to recovery was 5 days for those not on invasive ventilation and 13 days for those on invasive ventilation ($p<0.001$) (Figure 2A). Both pregnant and postpartum women on invasive ventilation had median time to recovery of 13 days ($p=0.53$, Figure 2A). Pregnant and postpartum women invasively ventilated at baseline had similar times to extubation (11 vs 7 days; $p=0.61$, Figure 2B). In the multivariate analysis, for

pregnant women, those on invasive mechanical ventilation at baseline had significantly longer time to recovery (HR [95% CI]: 0.34 [0.20, 0.59], p<0.0001). For postpartum women, those <35 years of age had a significantly shorter time to recovery (HR [95% CI]: 5.70 [1.01, 32.06]; p=0.0482). No baseline demographic or clinical disease characteristics, including duration of symptoms, examined were significantly associated with time to extubation.

Pregnancy Outcomes

We observed 45 total deliveries, including 26 among women who were pregnant at the time of remdesivir initiation and 19 among women who delivered prior to remdesivir initiation (postpartum group). Of all deliveries, 82% were cesarean and 86% of those were emergent cesarean (Appendix Figure 3A). Postpartum women had a numerically higher rate of cesarean delivery (95%) compared with women who initiated remdesivir while pregnant (73%). Of the 26 deliveries among pregnant women, 19 (73%) were cesarean and of these, 17 (89%) were emergent; 18 (69%) of the 26 neonates were delivered very preterm at 24 to 32 weeks gestation. Among the 19 postpartum women, 18 (95%) had a cesarean delivery, and of those, 15 were emergent (83%). Twelve (63%) of the 19 neonates were delivered very preterm at 24 to 32 weeks gestation. No obstetric indications for preterm delivery (e.g., spontaneous preterm labor, placental abruption or preeclampsia) were reported.

Among women who delivered during their hospitalization for COVID-19, most had a high-risk pregnancy due to underlying medical conditions: 69% of pregnant women were considered high risk, compared with 53% of postpartum women (Appendix Figure 3B). Rates of emergent cesarean delivery were similar in pregnant (86%) and postpartum women (80%) with a high-risk pregnancy.

Among the 45 deliveries, there were no neonatal deaths during the observation period. There was one spontaneous miscarriage at 17 weeks gestation in a 32-year-old woman with history of intravenous drug use, who was admitted with COVID19 and found to have concurrent *Staphylococcal aureus* bacteremia, tricuspid valve endocarditis, and septic arthritis.

Safety

In the overall cohort, 29% of women experienced an adverse event and 16% had a serious adverse event (Table 2). Among pregnant women, adverse events occurring in at least 3% of women included anemia, constipation, deep venous thrombosis, dysphagia, unspecified hypertension, hypoxia, nausea, and pleural effusion, reflecting signs and symptoms of pregnancy as well as COVID-19. Seven pregnant women discontinued study drug due to adverse events, including five due to elevations in liver enzymes concentration, one due to nausea and another due to hemoptysis. No postpartum women had any adverse events that led to discontinuation of remdesivir. One 30-year old woman, who received remdesivir after delivery, died in the postpartum period due to severe acute respiratory distress syndrome and associated cytokine storm; this death was attributed by the treating clinician to underlying COVID-19 and not to remdesivir.

In this compassionate use program, data were collected on a limited number of laboratory measures. Sixty-seven percent of all pregnant and postpartum women experienced any treatment-

emergent graded laboratory abnormality; most were Grade 1 or 2 (Table 2). Grade 3 elevations (>5x normal) in ALT and AST occurred in 9% and 5% of pregnant women, and 6% and 6% of postpartum women, respectively. There were no Grade 4 elevations (>10x normal) of ALT or AST in any women. Most creatinine elevations were grade 1 or 2. Grade 3 elevations in serum creatinine (>1.8x normal) occurred in 2% and 11% of pregnant and postpartum women, respectively; grade 4 elevations (>3.5x normal) occurred in 5% of pregnant women and no postpartum women.

DISCUSSION

We report experience of the first 86 pregnant women with severe COVID-19 treated in the remdesivir compassionate use program with 28 days of follow-up. While many women were critically ill at baseline, with 74% admitted to the ICU and 51% receiving invasive mechanical ventilation, recovery rates were high and treatment with remdesivir was safe and well tolerated.

Clinical recovery from severe COVID-19 was similarly high in women who initiated remdesivir during pregnancy (93%) or the immediate postpartum period (median postpartum day=1; range 0-3) (89%). However, pregnant women not requiring invasive mechanical ventilation at baseline had the highest rates of recovery (98%) and shortest median time to recovery (5 days). Postpartum women who delivered before initiating remdesivir had more critical illness at baseline, with 100% in the ICU and 95% requiring invasive ventilation. Due to the severity of their illness, these women were urgently delivered prior to initiation of remdesivir. When evaluating only those women receiving invasive ventilation at baseline, pregnant and postpartum women had the same median time to recovery (13 days).

In this cohort of women with severe COVID-19, deliveries were often very preterm (67% at <32 weeks gestational age) and by cesarean (82%); most cesarean deliveries were emergent (86%). Preterm deliveries were likely driven by the severity of maternal COVID-19 illness, as no obstetric indications for delivery were reported by clinicians, including no reports of spontaneous preterm labor, placental abruption or preeclampsia. Mechanical ventilation alone is not an indication for delivery, and in women <32 weeks gestation with severe hypoxemia, obstetric societies now recommend consideration of all other options before delivery, including prone positioning, ECMO, and other advanced ventilator methods.[20] Thus, the high number of preterm deliveries is consistent with national data, where a 75% rate of preterm birth was reported in pregnant women with critical COVID-19.[11]

Despite a high number of women with critical COVID-19 in our population, remdesivir was well tolerated. A low number of serious adverse events were observed and few led to discontinuation of therapy. No new safety signals were detected in this compassionate use cohort. The most common adverse events were related to pregnancy and underlying disease and most laboratory abnormalities were Grade 1 or 2. Grade 3 ALT or AST abnormalities were infrequent; no Grade 4 abnormalities were reported. Transient mild to moderate transaminase elevations have been observed following remdesivir exposure in healthy volunteers and patients infected with Ebola virus.[21] However, elevated transaminase levels are commonly seen in patients with severe COVID-19 prior to treatment.[22,23] There was one maternal death due to underlying disease and no neonatal deaths.

Interpretation of these data is limited as this was not a clinical trial but rather a compassionate use

program with small sample size, lack of placebo comparator arm, and incomplete obstetric and neonatal outcome data. In particular, as postpartum women who participated in this program had more severe COVID-19 disease during their pregnancy, our data may not be generalizable to women diagnosed in the postpartum period with milder disease. Moreover, safety and efficacy of remdesivir in women diagnosed in the postpartum period may be gleaned from adult randomized controlled trials.[6,24] Further investigation using a larger sample size and longer follow-up time is needed to the determine potentially variable effects of disease severity, pregnancy status, and delivery status on clinical outcomes. Furthermore, voluntary data entry into the online system occurred amidst challenges of clinical practice during the pandemic, and as such medical history, clinical course details, and adverse event reporting may not have been as systematically reported as in conventional clinical trials. Unlike dedicated laboratory tests conducted centrally for clinical trials, laboratory values from diverse clinical care settings and their local laboratories were individually entered, so data are only available on a limited number of relevant laboratory values. Data on viral shedding was not available universally and not collected for women or for delivered infants. We did not collect race or ethnicity data. Lastly, we would like to note that management of the disease has changed over time and continues to evolve with emerging data. The 86 women in our cohort were hospitalized and treated with remdesivir in the early days of the pandemic. Initially, some obstetric providers delivered patients early due to limited knowledge about the disease and concern for maternal/fetal decompensation. Our data also reflect a longer time from symptom onset to remdesivir initiation, which will likely decrease with evolving clinical practice.

Despite these limitations, these data from the first 86 pregnant women treated with remdesivir under compassionate use suggest that remdesivir was safe and well tolerated. Moreover, women in this analysis had higher rates of recovery than nonpregnant adults in the adult compassionate use program (92% vs. 62%),[25] although the two populations were different; for example, pregnant women were considerably younger (median age 33 versus 64 years). Finally, our results with remdesivir were achieved despite a high number of critically ill pregnant women, whereas among hospitalized pregnant women reported to the U.S. CDC with SARS-CoV-2 infection, only 4.6% had known ICU admission.[8]

Given recent data that pregnant women with COVID-19 are more likely to be admitted to the ICU and require invasive ventilation compared with nonpregnant women of reproductive age, the present analysis suggesting at least similar clinical and safety outcomes for remdesivir use in pregnant women provides a strong rationale to include pregnant women in remdesivir clinical trials and access programs, as has been strongly advocated for by those who care for pregnant women.[26-28]

CONCLUSION

Results from the compassionate use program provide strong support that remdesivir is safe in pregnant women with high rates of clinical recovery. Inclusion of pregnant women in future remdesivir clinical trials is essential to better characterize pharmacokinetics, safety, and efficacy of remdesivir use in pregnancy as well as neonatal outcomes in this understudied population.

NOTES

Acknowledgements

We would like to thank the women who participated in this program and their partners and families, and the principal investigators and their colleagues and staff, as well as the Gilead remdesivir compassionate use eligibility review team (Appendix). We express our solidarity with those who are or have been ill with Covid-19, their families, and the health care workers on the front lines of this pandemic. We also thank Sarah Tse, Gretchen Schmelz, and Deborah Ajayi (BioScience Communications) for preparing graphics, and Jill Dawson (independently employed) and Anna Kido (Gilead) for providing editorial assistance.

Program Oversight

For each patient treated with remdesivir under compassionate use, we obtained regulatory and institutional review board or independent ethics committee approval, with consent secured for all patients based on local regulations. The sponsor (Gilead Sciences) designed and carried out the program according to the single-patient protocol, collected the data, monitored program conduct, and performed all statistical analyses. All authors were given access to the reported data and took responsibility for their integrity and completeness. The initial draft of the manuscript was prepared by RMB and MD.

Funding

This work was funded by Gilead Sciences.

Conflicts of Interest

RMB reports grants and speaker and advisory board fees from Alexion Pharmaceuticals, outside the submitted work. SY has received payment from Gilead Sciences for participation in a Gilead advisory board regarding HIV medications as well as for acting as a sub-investigator for Gilead-sponsored HIV treatment trials in the HIV clinical trial unit, outside of the submitted work. KMM reports receiving grants paid to her institution from Gilead, outside the submitted work. OM reports grants from Lophius Biosciences, personal fees from Syneos, Merck Sharp & Dohme Corp (MSD), and Gilead, outside the submitted work. AD, LT, SKT YZ, TH, JH, APC, CC, MD, AOO, and DMB receive salary from Gilead as employees and are shareholders of Gilead stock. MDS reports grants from Aridis Pharmaceuticals Inc, Cidara Therapeutics, ContraFect, Cubist Pharmaceuticals Inc, Curetis Ag, Curetis GmBM, CutisPharma, DiaSorin Molecular LLC, Epigenomics Inc, EUROIMMUN US, Finch Therapeutics, Genentech USA Inc, Gilead Sciences, IBIS Biosystems, Iterum Therapeutics, Janssen Research and Development, LLC, Kinevant Sciences GmBH, Leonard-Meron Biosciences, Merck, Nabriva Therapeutics, NeuMoDx Molecular, Paratek Pharmaceuticals, Pfizer, Prenosis, Regeneron Pharmaceuticals, Sanofi Pasteur Inc, Seres Therapeutics Inc, Shire, and Summit Therapeutics, all outside the submitted work. KES, AYC, PS, BGB, EMK, AH, JFS, MES, SM, CB, GM, SJR, MN, IG, TV, OK, SD, GS, JSS, ZS, and WRS have no conflicts of interest to disclose.

REFERENCES

1. World Health Organization Coronavirus Disease (COVID-19) Dashboard. Available at https://covid19.who.int. Accessed July 30, 2020.

2. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-271.

3. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785-6797.

4. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020 Apr 22;2020.04.15.043166. (preprint)

5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report [published online ahead of print, 2020 May 22]. N Engl J Med. 2020;10.1056/NEJMoa2007764.

6. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. 2020;10.1056/NEJMoa2015301.

7. Food and Drug Administration Remdesivir EUA Letter of Authorization, May 1, 2020. Available at https://www.fda.gov/media/137564/download. Accessed July 20, 2020.

8. Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–June 7, 2020. MMWR. June 26, 2020;69;769–775.

9. WHO R&D Blueprint Novel Coronavirus, Covid-19 therapeutic trial synopsis, February 18, 2020. Available at https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf. Accessed July 20, 2020.

10. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458-464.

11. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. Am J Obstet Gynecol MFM. 2020;100134. (online ahead of print)

12. Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Jun 30]. Obstet Gynecol. 2020;10.1097/AOG.0000000000004050.

13. McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use remdesivir for treatment of severe COVID-19 in pregnant women at a United States academic center. Am J Obstet Gynecol MFM. 2020:100164. (Epub ahead of print)

14. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case Rep Womens Health. 2020;27:e00221.

15. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: results of a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2020.

16. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 May 22;NEJMoa2007764. doi: 10.1056/NEJMoa2007764. Online ahead of print.

17. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27. doi: 10.1056/NEJMoa2015301. Online ahead of print.

18. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382:1787-1799.

19. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed July 20, 2020.

20. Society for Maternal-Fetal Medicine. Management Considerations for Pregnant Patients With COVID-19, 7.2.2020. Available at: https://s3.amazonaws.com/cdn.smfm.org/media/2415/SMFM_COVID_Management_of_COVID_pos_preg_patients_7-2-20.PDF_.pdf. Accessed July 20, 2020.

21. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-303.

22. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428-430.

23. Feng G, Zheng KI, Yan Q-Q, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020;8:18–24.

24. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report [published online ahead of print, 2020 May 22]. N Engl J Med. 2020;NEJMoa2007764.

25. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;382:2327-2336.

26. Coalition to Advance Maternal Therapeutics letter to Dr. Francis Collins, Director NIH, and Dr. Stephen Hahn, Commissioner, FDA, March 18, 2020. Available at https://s3.amazonaws.com/cdn.smfm.org/media/2268/Final_CAMT_COVID_Letter_March_2020.pdf . Accessed July 20, 2020.

27. Society for Maternal-Fetal Medicine letter to Stephen J. Ubl, President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America and Scott Whitaker, President and Chief Executive Officer, Advanced Medical Technology Association, April 22, 2020. Available at https://s3.amazonaws.com/cdn.smfm.org/media/2329/COVID_Industry_Research.pdf. Accessed July 20, 2020.

29. LaCourse SM, John-Stewart G, Adams Waldorf KM. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials. Clin Infect Dis. 2020.ciaa444. (published online)

TABLES AND FIGURES

Table 1. Baseline Demographic and Clinical Characteristics

		Pregnant n=67	Postpartum n=19	All N=86
Age, y		33 (21–43)	34 (20–41)	33 (20–43)
<35 y		40 (60)	11 (58)	51 (59)
Gestational age, wk		28 (14, 39)	30 (27, 36)	29 (14, 39)
Gestational age category, wk	<24	12 (18)	0	12 (14)
	24–32	44 (66)	13 (72)	57 (67)
	>32	11 (16)	5 (28)	16 (19)
Duration of hospitalization, d		3 (2,5)	3 (2, 6)	3 (2, 5)
O_2-support category	Invasive	27 (40)	18 (95)	45 (52)
	IMV	27 (40)	17 (90)	44 (51)
	ECMO	0	1 (5)	1 (1)
	Noninvasive	40 (60)	1 (5)	41 (48)
	NIPPV	2 (3)	0	2 (2)
	High-flow O_2	10 (15)	1 (5)	11 (13)
	Low-flow O_2	25 (37)	0	25 (29)
	Room air	3 (4)	0	3 (3)
ICU setting		44 (67)	19 (100)	63 (74)
Duration of symptoms before RDV, d		9 (7, 11)	9 (6, 11)	9 (7, 11)
Any medical condition history		45 (67)	10 (53)	55 (64)
Comorbid conditions associated with increased pregnancy/COVID-19 risk	Obesity[†]	11 (16)	4 (21)	15 (17)
	Asthma	9 (13)	1 (5)	10 (12)
	Gestational diabetes	7 (10)	2 (11)	9 (10)
	Chronic hypertension	6 (9)	1 (5)	7 (8)
	Diabetes mellitus[‡]	7 (10)	—	7 (8)
	Preeclampsia	0	0	0

Median laboratory values	ALT, IU/L[¥]	24 (15, 36)	34 (18, 43)	26 (15, 39)
	AST, IU/L[¥]	30 (24, 48)	42 (31, 67)	32 (25, 56)

*Data are n (%) or median (interquartile range), except age and gestational age, which are median (range); †Includes abnormal body mass index (>35) and obesity; ‡Includes 2 patients with glucose intolerance.

[¥] At baseline ALT values ranged from 6 to 300 U/L and AST values ranged from 12 to 967 U/L.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IMV, invasive mechanical ventilation; IU/L, international units per liter; NIPPV, noninvasive positive-pressure ventilation; RDV, remdesivir.

Table 2. Overall Safety Summary

n (%)	Pregnant Women (n=67)	Postpartum Women (n=19)	All Women (n=86)
Any adverse event	22 (33)	3 (16)	25 (29)
Any adverse event in >1% overall			
Anemia	2 (3)	0	2 (2)
Constipation	2 (3)	0	2 (2)
Deep vein thrombosis	2 (3)	0	2 (2)
Dysphagia	2 (3)	0	2 (2)
Unspecified hypertension	2 (3)	0	2 (2)
Hypoxia	2 (3)	0	2 (2)
Nausea	2 (3)	0	2 (2)
Pleural effusion	2 (3)	0	2 (2)
ARDS	1 (1)	1 (5)	2 (2)
Any serious adverse event	12 (18)	2 (11)	14 (16)
Any adverse event leading to discontinuation	7 (10)	0	7 (8)
Death	0	1 (5)	1 (1)
Any Grade Laboratory Abnormality	42/67 (64)	14/18 (78)	56/84 (67)
Any Grade 3 or 4 Laboratory Abnormality	12/67 (18)	3/18 (17)	15/84 (18)
Relevant TE Lab Abnormalities			
ALT			
n	64	17	81
Grade 1	10 (16)	3 (18)	13 (16)
Grade 2	8 (13)	1 (6)	9 (11)
Grade 3	6 (9)	1 (6)	7 (9)
Grade 4	0	0	0
AST			
n	62	17	79
Grade 1	10 (16)	6 (35)	16 (20)
Grade 2	12 (19)	2 (12)	14 (18)
Grade 3	3 (5)	1 (6)	4 (5)
Grade 4	0	0	0
Creatinine			
n	65	18	83
Grade 1	2 (3)	2 (11)	4 (5)
Grade 2	5 (8)	2 (11)	7 (8)

Grade 3	1 (2)	2 (11)	3 (4)
Grade 4	3 (5)	0	3 (4)

ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate transaminase; TE, treatment emergent.

Treatment-emergent laboratory abnormalities were defined as results that increase at least 1 toxicity grade from baseline at any post baseline time point. If the relevant baseline laboratory result is missing, any abnormality of at least grade 1 observed post baseline is considered treatment-emergent.

FIGURE LEGENDS

Figure 1. Clinical outcomes in pregnant (A) and postpartum (B) women treated with remdesivir at D28. Mechanical ventilation includes invasive ventilation by endotracheal tube or tracheostomy. Blue shading indicates improvement from baseline oxygen support.

BL, baseline; NIPPV, non-invasive positive pressure ventilation; ECMO, extracorporeal membrane oxygenation.

Figure 2. Time to recovery and extubation in pregnant women who received remdesivir

Panel A shows time to recovery by baseline oxygen support status (invasive vs not invasive). Panel B shows time to extubation: baseline invasive oxygen support.

A Pregnant

Posttreatment O_2 Support Status — n (%)*	BL O_2 Support Status: 5 (ECMO/IMV) n=27†	4 (NIPPV/high-flow O_2) n=12	3 (low-flow O_2) n=25	2 (room air) n=3
6 (death)	0	0	0	0
5 (ECMO/IMV)	2 (7)	0	0	0
4 (NIPPV/high-flow O_2)	1 (4)	1 (8)	0	0
3 (low-flow O_2)	1 (4)	0	0	0
2 (room air)	1 (4)	0	1 (4)	0
1 (discharge)	22 (81)	11 (92)	24 (96)	3 (100)
Any improvement (≥1 point)	**93%** (25/27)	**92%** (11/12)	**100%** (25/25)	**100%** (3/3)

B Postpartum

Posttreatment O_2 Support Status — n (%)*	BL O_2 Support Status: 5 (ECMO/IMV) n=18†	4 (NIPPV/high-flow O_2) n=1	3 (low-flow O_2) n=0	2 (room air) n=0
6 (death)	1 (6)	0	0	0
5 (ECMO/IMV)	1 (6)	0	0	0
4 (NIPPV/high-flow O_2)	0	0	0	0
3 (low-flow O_2)	0	0	0	0
2 (room air)	1 (6)	0	0	0
1 (discharge)	15 (83)	1 (100)	0	0
Any improvement (≥1 point)	**89%** (16/18)	**100%** (1/1)	**0**	**0**

Worsened
No change
1-point improvement
≥2-point improvement